TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07564466: A Phase II Clinical Study to Evaluate the Efficacy and Safety of SKB571 in Participants With Gastrointestinal Tumors

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$12,289,200

Rescue Site Savings

+$8,131,200

Unlock Full NCT07564466 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07564466 Rescue Dossier →